Guggenheim Ups Eli Lilly (LLY) Price Target to $1,273 on Pipeline Strength
Guggenheim raises Eli Lilly (LLY) price target to $1,273, citing strong tirzepatide growth and retatrutide pipeline potential. Q2 earnings expected August 5. The post Guggenheim Ups Eli Lilly (LLY)…
Read the full articleYou might also wanna read
Guggenheim Upgrades Eli Lilly (LLY) Price Target Ahead of Q2 Earnings
Guggenheim increases Eli Lilly (LLY) price target to $1,273, projecting Q2 revenue above consensus. Retatrutide success probability raised t
Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma
Roughly $400 billion. That is how much market value Eli Lilly (NYSE:LLY) has added over the past year, with shares climbing from $773.86 on
Eli Lilly (NYSE:LLY) Shares Rise After Atai Partnership Could Unlock $1 Billion in Milestones
NEW YORK, July 16, 2026, 5:08 p.m. EDT – Shares of Eli Lilly (NYSE:LLY) edged higher on Thursday after the drugmaker announced a deal with A
Eli Lilly Revenue Surges 55.5% on Mounjaro Sales, But Stock Lags Amid Pricing Pressures
Eli Lilly reported strong revenue growth and raised full-year guidance, but pricing pressure and insider selling have limited the stock’s ne
briefly.co·27d agoAlnylam price target raised to $468 from $420 at Raymond James
See the rest of the story here . thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The F
Eli Lilly to Pay up to $3.8B for AtaiBeckley in Big Pharma’s Latest Psychedelic Foray
The deal gives Eli Lilly access to a psychedelic-based nasal spray that studies show curbs treatment-resistant depression in a single dose.
Comments
Sign in to join the conversation.
No comments yet. Be the first.